#Germany #Frankfurt #diagnostics #Anbio Biotechnology #Dry CLIA

Anbio Biotechnology Launches Dry Chemiluminescence Immunoassay (CLIA) Solution

Anbio Biotechnology, renowned for its pioneering contributions to diagnostic technology, has recently unveiled its Dry Chemiluminescence Immunoassay (CLIA) Solution, known as ADL-1000. This innovative tool is tailored to meet the increasing demand for rapid, dependable, and cost-effective diagnostic testing in various healthcare environments.

Key Features and Advantages

Revolutionary Freeze-Dried Reagents

One of the standout features of the ADL-1000 is its use of freeze-dried reagents. This breakthrough eliminates the necessity for cold chain logistics, allowing for storage and operation at room temperature. The stability of these reagents without refrigeration not only lowers operational costs but also simplifies logistical complexities associated with traditional refrigerated supplies.

Advanced Whole Blood Testing

The ADL-1000 is ushering in a new era of blood diagnostics with its onboard separation technology. This feature enables the system to process whole blood specimens into plasma directly, generating results with heightened accuracy without the need for conversions that can compromise data reliability.

Rapid Emergency Testing

Designed with emergency scenarios in mind, the CLIA solution includes a dedicated emergency testing slot. This allows for immediate processing of critical assays, delivering results in as little as 15 minutes. Such rapid turnaround times are vital for emergency departments where timely diagnostic information can be a matter of life and death.

Compact and Efficient Design

Occupying a minimal space of just 0.518m², the ADL-1000 is ideal for environments where space is limited. Despite its compact size, it boasts an impressive throughput of 180 tests per hour, ensuring healthcare providers can manage high volumes of tests efficiently.

Minimal Waste with Single-Test Flexibility

The ADL-1000 is designed for single-use testing on demand, significantly minimizing reagent waste. This feature not only enhances operational efficiency but also promotes sustainability by reducing unnecessary waste in medical settings.

Comprehensive Assay Portfolio

Beyond standard chemiluminescence applications, the ADL-1000 supports a rich portfolio of advanced diagnostics. These include specialized assays for conditions such as stroke, Alzheimer’s disease, thrombosis, and pre-eclampsia, addressing the diverse and evolving needs of modern healthcare practices.

A Remarkable Achievement in Diagnostic Technology

According to Michael Lau, CEO of Anbio Biotechnology, the launch of the Dry CLIA Solution marks a pivotal advancement in diagnostic technology. By offering unparalleled speed and accuracy, it addresses many of the logistical and operational challenges that healthcare providers face today.

About Anbio Biotechnology

Anbio Biotechnology stands out in the global medical device landscape, specializing in in vitro diagnostics. With a comprehensive portfolio that encompasses multiple medical sectors—including oncology, cardiology, infectious diseases, and beyond—Anbio is dedicated to transforming diagnostic care through innovative solutions and a focus on accessibility.

For further insights and updates regarding the Anbio Dry CLIA analyzer and the CE-marked Dry CLIA assays, follow Anbio on social media channels.